NavariRMKoellerJM.Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother2003;37:1276–86. DOI 10.1345/aph.1C510.
2.
Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London: Committee for Proprietary Medicinal Products, 1997.
3.
De PontiFPoluzziECavalliARecanatiniMMontanaroN.Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes: An overview. Drug Saf2002;25:263–86.
4.
FrothinghamR.Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy2001;21:1468–72.
5.
KoellerJAaproMGrallaRGrunbergSMHeskethPJKrisMGAntiemetic guidelines: Creating a more practical treatment approach. Support Care Cancer2002;10:519–22.
